Rosalba Torrisi
YOU?
Author Swipe
View article: PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors
PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors Open
Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel perme…
View article: Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort
Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort Open
Background/objectives: Pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is a solid indicator of favourable prognosis, potentially also being useful for more conservative patient management. We ai…
View article: Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy
Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy Open
Background CDK4/6 inhibitors (CDK4/6i) are cornerstone therapies in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) Breast Cancer (BC) and emerging evidence suggests that they may influence immune …
View article: Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients Open
The NATALEE trial expanded the use of adjuvant cyclin-dependent kinase 4/6 inhibitors beyond the MonarchE trial’s criteria for early breast cancer (eBC). We conducted a retrospective analysis comparing a large real-world (RW) cohort of 762…
View article: 425P Pain neuroscience education in early triple-negative breast cancer: A game changer for pain and quality of life?
425P Pain neuroscience education in early triple-negative breast cancer: A game changer for pain and quality of life? Open
View article: 389P Real-world feasibility, safety and treatment outcomes of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in elderly breast cancer patients
389P Real-world feasibility, safety and treatment outcomes of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in elderly breast cancer patients Open
View article: Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial)
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial) Open
The treatment of early triple-negative breast cancer (eTNBC) has improved patients’ prognosis but often leads to adverse events and sequelae affecting quality of life (QoL). Pain Neuroscience Education (PNE) is a promising non-pharmacologi…
View article: Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer Open
Background Abemaciclib-induced diarrhea is a relevant concern in clinical practice. Postbiotics have emerged as a promising option for managing it. Materials and Methods We conducted a retrospective-prospective, 2-group, observational stud…
View article: Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions Open
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main resistance mechanism to CDK4/6 inhibition in hormone-receptor positive (HR+) breast cancer. Additionally, consistent preclinical evidence states its crucial…
View article: Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer Open
Based on the unprecedented results observed in recent clinical trials, antibody-drug conjugates (ADCs) have revolutionized the treatment algorithm of metastatic breast cancer (mBC). The strategy of sequencing different ADCs in other lines …
View article: Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy Open
We investigated whether we could identify a panel of miRNAs associated with response to treatment in tumor tissues of patients with Hormone Receptor-positive/HER2-negative metastatic breast cancer treated with endocrine therapy (ET) and th…
View article: Dataset related to article "Profiling the Spectrum of Headache Disorders on 440 Breast Cancer Patients: Highlights on Clinical and Pathological Mechanisms"
Dataset related to article "Profiling the Spectrum of Headache Disorders on 440 Breast Cancer Patients: Highlights on Clinical and Pathological Mechanisms" Open
<p>This record contains raw data related to article "Profiling the Spectrum of Headache Disorders on 440 Breast Cancer Patients: Highlights on Clinical and Pathological Mechanisms"</p><p>Abstract</p><p>Althoug…
View article: Dataset related to article "Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib"
Dataset related to article "Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib" Open
<p><strong>Abstract</strong></p><p>In clinical trials testing abemaciclib in patients with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer, diarrhea is a very common adverse event…
View article: Dataset related to article "Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors "
Dataset related to article "Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors " Open
<p>This record contains raw data related to article "Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors"</p><p>Abstract</p><p><s…
View article: Dataset related to article "Identification of a panel of miRNAs associated with resistance to palbociclib and endocrine therapy"
Dataset related to article "Identification of a panel of miRNAs associated with resistance to palbociclib and endocrine therapy" Open
under definition
View article: Dataset related to article "Identification of a panel of miRNAs associated with resistance to palbociclib and endocrine therapy"
Dataset related to article "Identification of a panel of miRNAs associated with resistance to palbociclib and endocrine therapy" Open
under definition
View article: Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors
Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors Open
View article: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors Open
View article: Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study Open
Background In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based…
View article: Clinical Review on the Management of Breast Cancer Visceral Crisis
Clinical Review on the Management of Breast Cancer Visceral Crisis Open
Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10–15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative. As its clinical…
View article: Profiling the Spectrum of Headache Disorders on 440 Breast Cancer Patients: Highlights on Clinical and Pathological Mechanisms
Profiling the Spectrum of Headache Disorders on 440 Breast Cancer Patients: Highlights on Clinical and Pathological Mechanisms Open
Although widely studied, the association between migraines (M) and breast cancer (BC) risk remains evasive. In this prospective single-center study, 440 early or locally advanced BC patients were enrolled at IRCCS Humanitas Research Hospit…
View article: HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?
HR+/HER2– de novo metastatic breast cancer: a true peculiar entity? Open
De novo metastatic breast cancer (dnMBC) accounts for ~6-10% of all breast cancers and for ~30% of MBC with increasing incidence over time. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2
View article: Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib Open
In clinical trials testing abemaciclib in patients with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer, diarrhea is a very common adverse event (occurring in approximately 85% of patients, any grade). Nonethe…
View article: Dataset related to article "Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer"
Dataset related to article "Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer" Open
This record contains raw data related to article “Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer"\n\n\nAbstract\n\n\nWe retrospectively investigated in women treated…
View article: Dataset related to article "Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer"
Dataset related to article "Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer" Open
This record contains raw data related to article “Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer" Abstract We retrospectively investigated in women treated with fulvestrant for…
View article: Dataset related to article "Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial "
Dataset related to article "Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial " Open
This record contains raw data related to article “Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Rand…
View article: Dataset related to article "Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors "
Dataset related to article "Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors " Open
This record contains raw data related to article “Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors" Abstract Bone-active dru…
View article: Dataset related to article "Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial "
Dataset related to article "Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial " Open
This record contains raw data related to article “Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Rand…
View article: Dataset related to article "Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors "
Dataset related to article "Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors " Open
This record contains raw data related to article “Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors" Abstract Bone-active dru…
View article: Dataset related to article "Surgical management of BRCA-mutation carriers: A single institution experience"
Dataset related to article "Surgical management of BRCA-mutation carriers: A single institution experience" Open
This record contains raw data related to article “Surgical management of BRCA-mutation carriers: A single institution experience" Abstract: Introduction: The optimal surgical management of BRCA-mutation carriers remains a…